The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Disopain     2-[3,4-bis(4-methoxyphenyl)- 1,2-oxazol-5...

Synonyms: mofezolac, Mofezolaco, Mofezolacum, Mofezolac (TN), CHEMBL259972, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of mofezolac

  • When Apc gene knockout mice (APC1309 mice) were given 600 or 1200 p.p.m. mofezolac in their diet for 8 weeks, the numbers of intestinal polyps were also dose-dependently decreased, with reduction to 59% of that in the control diet group at the higher dose [1].
  • Administration of 300 ppm mofezolac plus 200 ppm nimesulide also significantly decreased polyp area in the intestine by 30% [2].
  • In contrast, COX activity in primary and consecutively cultured synovial cells isolated from osteoarthritis (OA) or normal arthritis was inhibited by NS-398, but not by mofezolac [3].
  • In the present study, we therefore investigated the effects of mofezolac on colon cancer development [4].
  • Treatment with 1200 ppm mofezolac significantly reduced the incidence, multiplicity and volume of colon carcinomas to 79%, 2.15 +/- 1.65 and 7.5 +/- 11.8 mm(3), respectively, compared with 94%, 3.19 +/- 1.87 and 23.7 +/- 31.2 mm(3) in the AOM treatment alone [4].

High impact information on mofezolac

  • The animals were treated with 300 or 600 ppm mofezolac (a COX-1 selective inhibitor) alone, 200 or 400 ppm nimesulide (a COX-2 selective inhibitor) alone, 300 ppm mofezolac plus 200 ppm nimesulide, 600 ppm mofezolac plus 400 ppm nimesulide, or 10 ppm indomethacin (a dual-COX inhibitor) in the diet from 7 weeks of age for 4 weeks [2].
  • Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis [1].
  • We therefore investigated whether a COX-1 selective inhibitor, mofezolac, suppresses intestinal carcinogenesis in rodents [1].
  • RESULTS: In normal rat, administration of indomethacin, relatively cyclooxygenase-1-selective inhibitor, mofezolac, or cyclooxygenase-2-selective inhibitors, NS-398 and JTE-522 had no effects on the escape latency against thermal stimuli [5].
  • Since IL-1ra suppresses the function of IL-1, a pro-inflammatory cytokine, the stimulatory effect of such NSAIDs as mofezolac on IL-1ra production could also be one of the mechanisms involved in its anti-inflammatory and antinociceptive actions [6].

Chemical compound and disease context of mofezolac


Anatomical context of mofezolac

  • Pharmacological experiments using mofezolac, a preferential inhibitor against COX-1, and NS-398, a selective inhibitor against COX-2, confirmed the involvement of COX-1 derived PGs in the induction of c-fos expression in the hind brain following the noxious stimulation [7].

Associations of mofezolac with other chemical compounds


Gene context of mofezolac

  • These data thus indicate that potent analgesic activity of mofezolac against the present model to be more closely related to its potent inhibitory activity against COX-1 but not against COX-2 [8].
  • These results confirm that COX-1, as well as COX-2, contributes to colon carcinogenesis and that mofezolac may be a good chemopreventive agent for human colon cancer [4].
  • Oral administration of mofezolac, a non-steroidal anti-inflammatory drug which potently inhibits COX-1, suppressed the PQ-induced writhing and peritoneal accumulation of PGs without affecting mRNA expression for both COX isoforms in mice [9].

Analytical, diagnostic and therapeutic context of mofezolac


  1. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Kitamura, T., Kawamori, T., Uchiya, N., Itoh, M., Noda, T., Matsuura, M., Sugimura, T., Wakabayashi, K. Carcinogenesis (2002) [Pubmed]
  2. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Kitamura, T., Itoh, M., Noda, T., Matsuura, M., Wakabayashi, K. Int. J. Cancer (2004) [Pubmed]
  3. Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients. Onodera, M., Horiuchi, Y., Nakahama, K., Muneta, T., Mano, Y., Morita, I. Inflamm. Res. (2004) [Pubmed]
  4. Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Niho, N., Kitamura, T., Takahashi, M., Mutoh, M., Sato, H., Matsuura, M., Sugimura, T., Wakabayashi, K. Cancer Sci. (2006) [Pubmed]
  5. Participation of cyclooxygenases in cutaneous thermal nociception under non-inflamed and inflamed conditions. Suzuki, M., Hayash, I., Nara, Y., Kumaga, Y., Okamoto, H., Hoka, S., Majima, M. Inflamm. Res. (2001) [Pubmed]
  6. Effects of nonsteroidal anti-inflammatory drugs on interleukin-1 receptor antagonist production in cultured human peripheral blood mononuclear cells. Kusuhara, H., Matsuyuki, H., Okumoto, T. Prostaglandins (1997) [Pubmed]
  7. Principal involvement of cyclooxygenase-1-derived prostaglandins in the c-fos expression of the rat hind brain following visceral stimulation with acetic acid. Kusuhara, H., Fukunari, A., Matsuyuki, H., Okumoto, T. Brain Res. Mol. Brain Res. (1997) [Pubmed]
  8. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Goto, K., Ochi, H., Yasunaga, Y., Matsuyuki, H., Imayoshi, T., Kusuhara, H., Okumoto, T. Prostaglandins Other Lipid Mediat. (1998) [Pubmed]
  9. Involvement of prostaglandins produced by cyclooxygenase-1 in murine visceronociception induced by phenylquinone. Kusuhara, H., Matsuyuki, H., Okumoto, T. Prostaglandins Other Lipid Mediat. (1998) [Pubmed]
  10. Mutagenicity tests of mofezolac (N-22). Ohuchida, A., Furukawa, A. The Journal of toxicological sciences. (1990) [Pubmed]
  11. Acute toxicity tests of mofezolac (N-22) in mice and rats. Satoh, K., Yamamoto, N., Kuwasaki, E., Ichiki, T., Sone, H., Kodama, R., Kuwata, M., Yamashita, K. The Journal of toxicological sciences. (1990) [Pubmed]
WikiGenes - Universities